P

Pikeville Medical Center | Research Department

Research site
(Unclaimed)
Location
911 Bypass Road, Pikeville, Kentucky, United States of America

Site insights

Top conditions

Top treatments

Paclitaxel
Carboplatin
Cisplatin
Bevacizumab
Topotecan
Lurbinectedin
Oxaliplatin
Capecitabine
Atezolizumab
Elotuzumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 17 total trials

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the phy...

Enrolling
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Drug: Fulvestrant
Drug: Dexamethasone Mouth Rinse

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Enrolling
Ischemic Stroke; Ischemic Attack, Transient
Drug: Placebo
Drug: Milvexian

The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for ca...

Active, not recruiting
Metastatic Adenocarcinoma of the Pancreas
Drug: Leucovorin
Drug: Gemcitabine

The purpose of this study is to assess the safety, pharmacokinetics, and immunogenicity of tiragolumab and atezolizumab intravenous fixed-dose combin...

Enrolling
PD-L1-selected Solid Tumors
Drug: Tiragolumab and Atezolizumab IV FDC

The purpose of the study (Part 1 and Part 2) is to evaluate the safety of a step-up dosing approach (starting with low doses followed by higher doses...

Active, not recruiting
Multiple Myeloma
Drug: Elranatamab
Locations recently updated

The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).

Enrolling
Small Cell Lung Cancer (SCLC)
Drug: Topotecan
Drug: Amrubicin

Trial sponsors

National Cancer Institute (NCI) logo
G
AbbVie logo
Amgen logo
Bristol-Myers Squibb (BMS) logo
G
Genentech logo
Ipsen logo
Janssen (J&J Innovative Medicine) logo
Jazz Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems